Effect of enzyme replacement therapy on the growth of patients with Morquio A

[1]  F. Deodato,et al.  Enzyme replacement therapy: efficacy and limitations , 2018, Italian Journal of Pediatrics.

[2]  S. Khan,et al.  Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis. , 2018, Molecular genetics and metabolism.

[3]  C. Pizarro,et al.  Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA. , 2018, Molecular genetics and metabolism.

[4]  Yasuyuki Suzuki,et al.  Growth impairment in mucopolysaccharidoses. , 2018, Molecular genetics and metabolism.

[5]  S. Tomatsu,et al.  Neurophysiology of hearing in patients with mucopolysaccharidosis type IV. , 2018, Molecular genetics and metabolism.

[6]  C. Pizarro,et al.  Natural history of Morquio A patient with tracheal obstruction from birth to death , 2017, Molecular genetics and metabolism reports.

[7]  Y. Puckett,et al.  Enzyme Replacement Therapy with Elosulfase alfa for Mucopolysaccharidosis IVA (Morquio A Syndrome): Milestones and Challenges , 2017 .

[8]  Marianne Rohrbach,et al.  Epidemiology of mucopolysaccharidoses. , 2017, Molecular genetics and metabolism.

[9]  S. Khan,et al.  Mucopolysaccharidosis IVA and glycosaminoglycans. , 2017, Molecular genetics and metabolism.

[10]  S. Ragot,et al.  30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case , 2016, Molecular genetics and metabolism reports.

[11]  C. Pizarro,et al.  Surgical Reconstruction for Severe Tracheal Obstruction in Morquio A Syndrome. , 2016, The Annals of thoracic surgery.

[12]  T. Rahman,et al.  Activity of daily living for Morquio A syndrome. , 2016, Molecular genetics and metabolism.

[13]  Yasuyuki Suzuki,et al.  Hematopoietic stem cell transplantation for Morquio A syndrome. , 2016, Molecular genetics and metabolism.

[14]  C. Pizarro,et al.  Obstructive airway in Morquio A syndrome, the past, the present and the future. , 2016, Molecular genetics and metabolism.

[15]  T. Shimada,et al.  Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations , 2015, Expert opinion on orphan drugs.

[16]  A. Shaywitz,et al.  Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y , 2015, Pediatric Research.

[17]  T. Shimada,et al.  Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome , 2015, Drug design, development and therapy.

[18]  C. Hendriksz,et al.  Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial. , 2015, Molecular genetics and metabolism.

[19]  W. Sly,et al.  Therapies for the bone in mucopolysaccharidoses. , 2015, Molecular genetics and metabolism.

[20]  A. Shaywitz,et al.  Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome , 2014, Clinical Pharmacokinetics.

[21]  T. Fleming,et al.  Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study , 2014, Journal of Inherited Metabolic Disease.

[22]  Yasuyuki Suzuki,et al.  Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA , 2014, Molecular genetics and metabolism reports.

[23]  G. Mitchell,et al.  Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. , 2013, Molecular genetics and metabolism.

[24]  C. Hendriksz,et al.  Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. , 2013, Molecular genetics and metabolism.

[25]  R. Giugliani,et al.  Impairment of Body Growth in Mucopolysaccharidoses , 2012 .

[26]  J. Clarke,et al.  Treatment of Lysosomal Storage Disorders , 2012, Drugs.

[27]  Y. Suzuki,et al.  Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. , 2011, Current pharmaceutical biotechnology.

[28]  Hirotaka Oikawa,et al.  Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  S. Tomatsu,et al.  Sacral dimple: incidental findings from newborn evaluation (Case Presentation) , 2009, Acta paediatrica.

[30]  W. Sly,et al.  Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. , 2008, Molecular genetics and metabolism.

[31]  S. Tomatsu,et al.  Growth charts for patients affected with Morquio A disease , 2008, American journal of medical genetics. Part A.

[32]  W. Sly,et al.  Enzyme replacement therapy in a murine model of Morquio A syndrome. , 2007, Human molecular genetics.

[33]  L. de Meirleir,et al.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy , 2007, European Journal of Pediatrics.

[34]  Avan Aihie Sayer,et al.  Growth in early life predicts bone strength in late adulthood: The Hertfordshire Cohort Study , 2007, Bone.

[35]  S. Tomatsu,et al.  International Morquio A Registry: Clinical manifestation and natural course of Morquio A disease , 2007, Journal of Inherited Metabolic Disease.

[36]  S. Tomatsu,et al.  Determinant factors of spectrum of missense variants in mucopolysaccharidosis IVA gene. , 2006, Molecular genetics and metabolism.

[37]  W. Sly,et al.  Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. , 2006, Molecular genetics and metabolism.

[38]  M. Connock,et al.  A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. , 2006, Health technology assessment.

[39]  O. Amaral,et al.  Prevalence of lysosomal storage diseases in Portugal , 2004, European Journal of Human Genetics.

[40]  J. Belmont,et al.  Enzyme-replacement therapy in mucopolysaccharidosis I. , 2001, The New England journal of medicine.

[41]  Y. Masamune,et al.  Novel Drug Delivery System to Bone Using Acidic Oligopeptide: Pharmacokinetic Characteristics and Pharmacological Potential , 2001, Journal of drug targeting.

[42]  D. Applegarth,et al.  Incidence of Inborn Errors of Metabolism in British Columbia, 1969–1996 , 2000, Pediatrics.

[43]  R. A. Wevers,et al.  The frequency of lysosomal storage diseases in The Netherlands , 1999, Human Genetics.

[44]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[45]  J. Nelson,et al.  Incidence of the mucopolysaccharidoses in Northern Ireland , 1997, Human Genetics.